ClinicalTrials.gg
CompletedNCT00143455Updated Feb 18, 2010Results posted

Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer

A Phase 3 interventional study of Etoposide + cisplatin and Irinotecan + cisplatin in Small Cell Lung Carcinoma, sponsored by Pfizer. Completed at 68 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-02-18.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
485
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing etoposide in Small Cell Lung Carcinoma — 9 open to participants now, 11 under way, 1 of them phase 3. Etoposide · Small Cell Lung Carcinoma.

Enrollment
2nd of 44
485 · median 59
Started
2002
the only one that year
Phase 3
9 of 44
1 open now
Registered
9th of 44
by date

Among the 44 studies testing etoposide in Small Cell Lung Carcinoma, this one is the 2nd largest by enrollment, is the only one that started in 2002, is one of 9 in phase 3, and was the 9th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

9 of the 44 studies testing etoposide in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About etoposide

Etoposide: first FDA approval 1983 (VEPESID). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing etoposide in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung Cancer (ED-SCLC).

03

Conditions studied

  • Small Cell Lung Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven Small Cell Lung Cancer (SCLC)
  • : 0, 1

Exclusion criteria

Exclusion Criteria:

  • No previous radiotherapy is allowed except on bone when newly diagnosed. Radiotherapy is not allowed for vena cava syndrome, a stent is recommended ;
  • No prior surgery on the primary tumor except for palliative purpose (stent for vena cava syndrome).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
485 participants (actual)

Study arms

  • Experimental
    B

    Drug: Etoposide + cisplatin

  • Experimental
    A

    Drug: Irinotecan + cisplatin

Interventions

  • DrugEtoposide + cisplatin

    Drug pages: Etoposide · Cisplatin

    etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle

  • DrugIrinotecan + cisplatin

    Drug pages: Irinotecan · Cisplatin

    irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) for the Full Analysis Population (FAP)

    OS was defined as the time from date of randomization to date of death due to any cause. For a subject not expiring, the OS time was censored on the last date of contact that they were known to be alive. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.

    Time frame: Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment)

  2. Overall Survival for the Per Protocol (PP) Population

    OS was defined as the time from date of randomization to date of death due to any cause. For a subject not expiring, the OS time was censored on the last date of contact that they were known to be alive. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.

    Time frame: Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment)

Secondary outcomes

  1. Number of Subjects With Overall Confirmed Response

    Objective disease response = subjects with confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target lesions. A PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Baseline to first documentation of confirmed response (every 9 weeks for up to 6 months on study treatment and every 2 months in follow up until progression)

  2. Duration of Response (DR)

    DR was defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.

    Time frame: Baseline to first documentation of confirmed response (every 9 weeks for up to 6 months on study treatment and every 2 months in follow up until progression)

  3. Time to Tumor Progression (TTP)

    TTP was defined as the time from date of randomization to the date of the first documentation of tumor progression. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.

    Time frame: Baseline to date of progression (every 9 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment until progression)

  4. European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30)

    The EORTC QLQ-C30 scales include 5 functional scales (physical, role, cognitive, emotional, and social), a global health status/QL scale and 9 symptom scales: nausea and vomiting, pain, fatigue, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties. All scales and single-item measures range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, for the global health status/QL represents a high QL (better patient state), and for a symptom scale/item represents a high level of symptomatology/problems (worse patient state).

    Time frame: Baseline, at every cycle (Day -1, Day 1 of cycle before treatment), at the end of the treatment, and every 2 months during follow-up

  5. Tumor Related Symptoms (Pain, Dyspnea, Cough, Hemoptysis, Weight, and the Use of Opioids and Non-Opioids Analgesics)

    Improvement of ≥ 1 tumor related symptom = clinical benefit responder. Pain improvement = decrease of ≥ 1 National Cancer Institute (NCI) grade from baseline of ≥ 1 symptom of NCI pain category, without pain symptom worsening. Cough, dyspnea and hemoptysis improvement = decrease of ≥ 1 NCI grade from baseline. Positive weight change ≥ 5 percent gain from baseline. Positive analgesic consumption = change from baseline from opioid to non-opioid category.

    Time frame: Every 3 weeks for up to 6 months on study treatment

07

Results

Posted Jan 21, 2010

Participant flow

Enrollment of Cohort 1 was terminated early per protocol amendment (29 September 2003). With limited number of subjects in Cohort 1, the efficacy analysis was exploratory. The amendment reduced Irinotecan dose from 80 to 65 mg/m2. With the study powered for Overall Survival in subjects recruited thereafter (Cohort 2) efficacy analysis is reported.

Cohort 1
Participant flow — Cohort 1
MilestoneIrinotecan + Cisplatin (Cohort 1)Etoposide + Cisplatin (Cohort 1)Irinotecan + Cisplatin (Cohort 2)Etoposide + Cisplatin (Cohort 2)
Started393900
Received treatment393800
Completed252200
Not completed141700
Withdrew: Adverse event8400
Withdrew: Death5200
Withdrew: Progressive disease0600
Withdrew: Withdrawal by subject1400
Withdrew: Randomized but not treated0100
Cohort 2
Participant flow — Cohort 2
MilestoneIrinotecan + Cisplatin (Cohort 1)Etoposide + Cisplatin (Cohort 1)Irinotecan + Cisplatin (Cohort 2)Etoposide + Cisplatin (Cohort 2)
Started00203204
Received treatment00202203
Completed0097111
Not completed0010693
Withdrew: Adverse event004230
Withdrew: No longer required study treatment0010
Withdrew: Protocol violation0011
Withdrew: Lost to follow-up0014
Withdrew: Death002012
Withdrew: Progressive disease002027
Withdrew: Withdrawal by subject001312
Withdrew: Other0076
Withdrew: Randomized but not treated0011

Outcome measures

PrimaryOverall Survival (OS) for the Full Analysis Population (FAP)

OS was defined as the time from date of randomization to date of death due to any cause. For a subject not expiring, the OS time was censored on the last date of contact that they were known to be alive. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.

Time frame:
Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment)
Reported as:
Median · months
Overall Survival (OS) for the Full Analysis Population (FAP)
monthsIrinotecan + Cisplatin (Cohort 1)Etoposide + Cisplatin (Cohort 1)Irinotecan + Cisplatin (Cohort 2)Etoposide + Cisplatin (Cohort 2)
Overall Survival (OS) for the Full Analysis Population (FAP)——10.2177 (8.9692 to 11.6632)9.6591 (8.9363 to 11.0719)
Statistical analysis
  • Irinotecan + Cisplatin (Cohort 2) vs Etoposide + Cisplatin (Cohort 2) · Cox Proportional Hazard Model · p = 0.0556 · Hazard ratio (hr): 1.236 · 95% CI 0.995 to 1.536
SecondaryNumber of Subjects With Overall Confirmed Response

Objective disease response = subjects with confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target lesions. A PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Baseline to first documentation of confirmed response (every 9 weeks for up to 6 months on study treatment and every 2 months in follow up until progression)
Reported as:
Number · participants
Number of Subjects With Overall Confirmed Response
participantsIrinotecan + Cisplatin (Cohort 1)Etoposide + Cisplatin (Cohort 1)Irinotecan + Cisplatin (Cohort 2)Etoposide + Cisplatin (Cohort 2)
Number of Subjects With Overall Confirmed Response——7994
Statistical analysis
  • Irinotecan + Cisplatin (Cohort 2) vs Etoposide + Cisplatin (Cohort 2) · Chi-squared · p = 0.143 · Odds ratio (or): 1.343 · 95% CI 0.905 to 1.993
PrimaryOverall Survival for the Per Protocol (PP) Population

OS was defined as the time from date of randomization to date of death due to any cause. For a subject not expiring, the OS time was censored on the last date of contact that they were known to be alive. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.

Time frame:
Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment)
Reported as:
Median · months
Overall Survival for the Per Protocol (PP) Population
monthsIrinotecan + Cisplatin (Cohort 2)Etoposide + Cisplatin (Cohort 2)
Overall Survival for the Per Protocol (PP) Population10.5791 (9.2977 to 12.2875)9.4292 (8.5092 to 10.1848)
Statistical analysis
  • Irinotecan + Cisplatin (Cohort 2) vs Etoposide + Cisplatin (Cohort 2) · Cox Proportional Hazard Model · p = 0.0110 · Hazard ratio (hr): 1.350 · 95% CI 1.071 to 1.701
SecondaryDuration of Response (DR)

DR was defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.

Time frame:
Baseline to first documentation of confirmed response (every 9 weeks for up to 6 months on study treatment and every 2 months in follow up until progression)
Reported as:
Median · months
Duration of Response (DR)
monthsIrinotecan + Cisplatin (Cohort 1)Etoposide + Cisplatin (Cohort 1)Irinotecan + Cisplatin (Cohort 2)Etoposide + Cisplatin (Cohort 2)
Duration of Response (DR)——5.5195 (4.8953 to 6.1437)4.8953 (4.8296 to 5.2895)
Statistical analysis
  • Irinotecan + Cisplatin (Cohort 2) vs Etoposide + Cisplatin (Cohort 2) · Cox Proportional Hazard Model · p = 0.0831 · Hazard ratio (hr): 1.354 · 95% CI 0.961 to 1.908
SecondaryTime to Tumor Progression (TTP)

TTP was defined as the time from date of randomization to the date of the first documentation of tumor progression. The Kaplan-Meier method was used to analyze variables of duration and event associated with possible censoring and estimate the medians survival by treatment groups. The confidence intervals for the medians were calculated using the Brookmeyer and Crowley's method.

Time frame:
Baseline to date of progression (every 9 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment until progression)
Reported as:
Median · months
Time to Tumor Progression (TTP)
monthsIrinotecan + Cisplatin (Cohort 1)Etoposide + Cisplatin (Cohort 1)Irinotecan + Cisplatin (Cohort 2)Etoposide + Cisplatin (Cohort 2)
Time to Tumor Progression (TTP)——5.3552 (4.9281 to 6.2423)6.2423 (5.6838 to 6.7023)
Statistical analysis
  • Irinotecan + Cisplatin (Cohort 2) vs Etoposide + Cisplatin (Cohort 2) · Cox Proportional Hazard Model · p = 0.7544 · Hazard ratio (hr): 0.965 · 95% CI 0.771 to 1.208
SecondaryEuropean Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30)

The EORTC QLQ-C30 scales include 5 functional scales (physical, role, cognitive, emotional, and social), a global health status/QL scale and 9 symptom scales: nausea and vomiting, pain, fatigue, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties. All scales and single-item measures range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, for the global health status/QL represents a high QL (better patient state), and for a symptom scale/item represents a high level of symptomatology/problems (worse patient state).

Time frame:
Baseline, at every cycle (Day -1, Day 1 of cycle before treatment), at the end of the treatment, and every 2 months during follow-up
Reported as:
Mean · scores on a scale

No measurements were reported for this outcome.

SecondaryTumor Related Symptoms (Pain, Dyspnea, Cough, Hemoptysis, Weight, and the Use of Opioids and Non-Opioids Analgesics)

Improvement of ≥ 1 tumor related symptom = clinical benefit responder. Pain improvement = decrease of ≥ 1 National Cancer Institute (NCI) grade from baseline of ≥ 1 symptom of NCI pain category, without pain symptom worsening. Cough, dyspnea and hemoptysis improvement = decrease of ≥ 1 NCI grade from baseline. Positive weight change ≥ 5 percent gain from baseline. Positive analgesic consumption = change from baseline from opioid to non-opioid category.

Time frame:
Every 3 weeks for up to 6 months on study treatment
Reported as:
Number · participants

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Irinotecan + Cisplatin (Cohort 1)—9/39 (23.1%)39/39 (100%)
Etoposide + Cisplatin (Cohort 1)—4/38 (10.5%)38/38 (100%)
Irinotecan + Cisplatin (Cohort 2)—45/202 (22.3%)202/202 (100%)
Etoposide + Cisplatin (Cohort 2)—29/203 (14.3%)203/203 (100%)
Most frequent serious events
Showing 10 of 168
Most frequent serious events
EventIrinotecan + Cisplatin (Cohort 1)Etoposide + Cisplatin (Cohort 1)Irinotecan + Cisplatin (Cohort 2)Etoposide + Cisplatin (Cohort 2)
FatigueGeneral disorders7/394/3825/20214/203
Diarrhoea NOSGastrointestinal disorders5/391/3833/2025/203
NauseaGastrointestinal disorders6/392/3823/20212/203
Weight decreasedInvestigations6/390/3820/20210/203
Dyspnoea NOSRespiratory, thoracic and mediastinal disorders5/392/3830/20222/203
Vomiting NOSGastrointestinal disorders5/392/3822/2027/203
CoughRespiratory, thoracic and mediastinal disorders4/392/3825/20215/203
Leukopenia NOSBlood and lymphatic system disorders3/391/3810/2025/203
Bone painMusculoskeletal and connective tissue disorders3/391/387/2028/203
General physical health deteriorationGeneral disorders0/390/3814/2029/203
Most frequent other events
Showing 10 of 59
Most frequent other events
EventIrinotecan + Cisplatin (Cohort 1)Etoposide + Cisplatin (Cohort 1)Irinotecan + Cisplatin (Cohort 2)Etoposide + Cisplatin (Cohort 2)
FatigueGeneral disorders28/3927/38131/202123/203
Dyspnoea NOSRespiratory, thoracic and mediastinal disorders21/3922/38134/202139/203
NauseaGastrointestinal disorders23/3922/38135/202123/203
NeutropeniaBlood and lymphatic system disorders18/3918/38107/202131/203
CoughRespiratory, thoracic and mediastinal disorders24/3923/38130/202130/203
AlopeciaSkin and subcutaneous tissue disorders14/3922/3878/202103/203
Diarrhoea NOSGastrointestinal disorders17/394/38113/20228/203
Vomiting NOSGastrointestinal disorders18/3918/38112/20284/203
Weight decreasedInvestigations20/3912/3883/20261/203
AnorexiaMetabolism and nutrition disorders16/3911/3881/20266/203

Baseline characteristics

Age, Customized
Age, Customized(participants)Irinotecan + Cisplatin (Cohort 1)Etoposide + Cisplatin (Cohort 1)Irinotecan + Cisplatin (Cohort 2)Etoposide + Cisplatin (Cohort 2)Total
18 to 44 years2111620
45 to 64 years2724134130315
> = 65 years10135767147
Sex: Female, Male
Sex: Female, Male(Participants)Irinotecan + Cisplatin (Cohort 1)Etoposide + Cisplatin (Cohort 1)Irinotecan + Cisplatin (Cohort 2)Etoposide + Cisplatin (Cohort 2)Total
Female774848110
Male3231154155372
08

Study locations

68 sites
  • Pfizer Investigational Site
    Wels, A-4600, Austria
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Leuven, 3000, Belgium
  • Pfizer Investigational Site
    Liège, 4000, Belgium
  • Pfizer Investigational Site
    Brno-Bohunice, 625 00, Czech Republic
  • Pfizer Investigational Site
    Olomouc, 775 20, Czech Republic
  • Pfizer Investigational Site
    Ostrava - Poruba, 708 52, Czech Republic
  • Pfizer Investigational Site
    Prague, 150 06, Czech Republic
  • Pfizer Investigational Site
    Praha 8, 180 81, Czech Republic
  • Pfizer Investigational Site
    Usti Nad Labem, 401 13, Czech Republic
  • Pfizer Investigational Site
    Alexandria, Egypt
  • Pfizer Investigational Site
    Cairo, Egypt
  • Pfizer Investigational Site
    Amiens Cedex 1, 80054, France
  • Pfizer Investigational Site
    Bobigny, 93009, France
  • Pfizer Investigational Site
    Bordeaux, 33076, France
  • Pfizer Investigational Site
    Brest, 29200, France
  • Pfizer Investigational Site
    Caen Cedex 05, 14076, France
  • Pfizer Investigational Site
    Limoges, 87042, France
  • Pfizer Investigational Site
    Marseille Cedex 9, 13273, France
  • Pfizer Investigational Site
    Meaux, France
  • Pfizer Investigational Site
    Mulhouse, 68070, France
  • Pfizer Investigational Site
    Pierre-Bénite, 69310, France
  • Pfizer Investigational Site
    Rennes, 35033, France
  • Pfizer Investigational Site
    Rouen Cedex 1, 76031, France
  • Pfizer Investigational Site
    Saint Brieuc, 22015, France
  • Pfizer Investigational Site
    Saint Etienne, 42055, France
  • Pfizer Investigational Site
    Saint Pierre, 97448, France
  • Pfizer Investigational Site
    Villefranche Sur Saone, 69655, France
  • Pfizer Investigational Site
    Villejuif, 94805, France
  • Pfizer Investigational Site
    Bad Berka, 99437, Germany
  • Pfizer Investigational Site
    Berlin, 14165, Germany
  • Pfizer Investigational Site
    Bovenden-Lenglern, 37120, Germany
  • Pfizer Investigational Site
    Ebensfeld, 96250, Germany
  • Pfizer Investigational Site
    Gauting, 82131, Germany
  • Pfizer Investigational Site
    Goettingen, 37075, Germany
  • Pfizer Investigational Site
    Grosshansdorf, 22927, Germany
  • Pfizer Investigational Site
    Hamburg, 21057, Germany
  • Pfizer Investigational Site
    Heidelberg, 69126, Germany
  • Pfizer Investigational Site
    Hemer, 58656, Germany
  • Pfizer Investigational Site
    Loewenstein, 74245, Germany
  • Pfizer Investigational Site
    Muenchen, 81675, Germany
  • Pfizer Investigational Site
    Bologna, 40139, Italy
  • Pfizer Investigational Site
    Perugia, 06122, Italy
  • Pfizer Investigational Site
    Amsterdam, 1091 HA, Netherlands
  • Pfizer Investigational Site
    Breda, 4819 EV, Netherlands
  • Pfizer Investigational Site
    Groningen, 9700 RM, Netherlands
  • Pfizer Investigational Site
    Maastricht, 6229 HX, Netherlands
  • Pfizer Investigational Site
    Nieuwegein, 3435 CM, Netherlands
  • Pfizer Investigational Site
    Lodz, 93-509, Poland
  • Pfizer Investigational Site
    Otwock, 05-400, Poland
  • Pfizer Investigational Site
    Poznan, 60-569, Poland
  • Pfizer Investigational Site
    Warsaw, 02-781, Poland
  • Pfizer Investigational Site
    Warszawa, 02-781, Poland
  • Pfizer Investigational Site
    Moscow 115 478, Russian Federation
  • Pfizer Investigational Site
    Moscow, 121356, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 189646, Russian Federation
  • Pfizer Investigational Site
    Barcelona, 08907, Spain
  • Pfizer Investigational Site
    Madrid, 28040, Spain
  • Pfizer Investigational Site
    Aarau, CH-5001, Switzerland
  • Pfizer Investigational Site
    Basel, CH-4031, Switzerland
  • Pfizer Investigational Site
    Bellinzona, CH-6500, Switzerland
  • Pfizer Investigational Site
    Bern, CH-3010, Switzerland
  • Pfizer Investigational Site
    Ch-4101 Bruderholz, Switzerland
  • Pfizer Investigational Site
    Thun, CH-3600, Switzerland
  • Pfizer Investigational Site
    Taichung, 407, Taiwan
  • Pfizer Investigational Site
    Taipei, 100, Taiwan
  • Pfizer Investigational Site
    Taipei, Taiwan
  • Pfizer Investigational Site
    Taoyuan, Taiwan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2005
First posted
Sep 2, 2005
Start
Jun 2002
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Jan 21, 2010
Last update
Feb 18, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00143455
Lead sponsor
Pfizer
First posted
Sep 2, 2005
Start date
Jun 2002
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Jan 21, 2010
Last update
Feb 18, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Etoposide · Cisplatin · Irinotecan

Start the discussion